Updates are available Correction dated 2023-05-12

Article History

Received: 2 December 2022

Accepted: 5 March 2023

First Online: 1 April 2023

Change Date: 12 May 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12282-023-01468-z

Declarations

:

: Hideko Yamauchi reports research funding from AstraZeneca and Eiken. Masakazu Toi reports research grants from AFI technology, Astellas, AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly and companies, GL Science, JBCRG assoc., KBCRN assoc., Luxonus, Nippon Kayaku, Pfizer, Sanwa Shurui, Shimadzu, Shionogi, Taiho, Takeda, and Yakult; lecture chair or honoraria from AstraZeneca, Chugai, Daiichi-Sankyo, Devicore medical Japan, Eisai, Eli Lilly and companies, Exact Science, Kyowa-Kirin, Merck Sharp & Dohme Corp, Nippon Kayaku, Novartis, Pfizer, Shimadzu, Sysmex, Taiho, Takeda, and Yakult; participation on advisory boards with Athenex Oncology, Bertis, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly and companies, Kansai Medical Net, and Terumo; being a member of the board of directors (with no salary) for JBCRG assoc., KBCRN assoc., and NPO org. OOTR; being an associate editor for <i>Asian Journal of Breast Surgery</i>, <i>Asian Journal of Surgery</i>, <i>Breast Cancer Research and Treatment</i>, <i>British Journal of Cancer</i>, <i>Cancer Science</i>, <i>Frontiers in Women’s Cancer</i>, and <i>Scientific Reports</i>; and being a deputy editor for <i>International Journal of Oncology</i>. Shin Takayama reports support for the present manuscript from AstraZeneca. Seigo Nakamura reports support for the present manuscript and honoraria from AstraZeneca. Toshimi Takano reports lecture honoraria from Celltrion, Chugai, Daiichi-Sankyo, Eisai, and Eli Lilly and companies. Karen Cui reports an advisory or officer position with AstraZeneca; and ownership of stock in AstraZeneca, and Bristol-Myers Squibb. Christine Campbell reports salary support from AstraZeneca for work involved in the conduct and management of the trial, including travel to study management meetings, paid to her institution via contract with non-profit organizations; and an advisory or officer position with Frontier Sciences (Scotland). Liesbet De Vos reports receiving funding to her institution from AstraZeneca, Biovica, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, Sanofi, and Servier; Royalties or licenses to her institution from Agendia; and an advisory or officer position with Breast International Group. Charles Geyer reports grants to his institution from AbbVie, AstraZeneca, Daiichi-Sankyo, and Genentech/Roche; consulting fees from Athenex; medical writing payment or honoraria from AbbVie, and Genentech/Roche; support for attending meetings and/or travel from AstraZeneca, Daiichi-Sankyo, and Genentech/Roche; compensated participation on advisory boards for Exact Sciences; and uncompensated participation on advisory boards for Daiichi-Sankyo, Genentech/Roche, and SeaGen. Andrew Tutt reports consulting/advisor/honoraria from Pfizer, Artios, Prime Oncology, Gilead, Merck KGaA; Advisory Board funds to his institution from Gilead, AstraZeneca; Research funding to his institution from AstraZeneca, Merck KGaA; expert testimony fees from EM Partners; Stocks–Inbiomotion. Royalty associated payments—ICR rewards to inventor's scheme payments associated with patent for the use of PARP inhibitors in DNA deficient cancers, licensee—AstraZeneca. Other, Grant funded by Breast Cancer Now (BCN) and Cancer Research UK (CRUK) to study homologous recombination deficient breast and other cancers, BCN/CRUK receive payments associated with a patent for the use of PARP inhibitors in DNA deficient cancers, licensee—AstraZeneca.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, as well as Good Clinical Practice guidelines and the AstraZeneca policy on bioethics.

: Informed consent was obtained from all individual participants included in the study.